Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program

Overview of attention for article published in Therapeutics and Clinical Risk Management, October 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter: 14 X users

facebook: 1 Facebook page

Readers on

mendeley: 71 Mendeley

Summary X Facebook

So far, Altmetric has seen 1 public wall post.

Advanced Neurosciences Institute, 04 Nov 2017

Retweeted OhioHealthMS (@OhioHealthMS): Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple…